National Cancer Institute (NCI)

New phase 1_2 trial NCT03190941 posted by National Cancer Institute (NCI): "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients". New trial on a phase 1_2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 15 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 2 trial NCT05638295 posted by National Cancer Institute (NCI): "Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)". New trial on a phase 2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 118 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 2 trial NCT03155620 posted by National Cancer Institute (NCI): "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)". New trial on a phase 2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 46 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

New phase 1_2 trial NCT02079740 posted by National Cancer Institute (NCI): "Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors". New trial on a phase 1_2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 103 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

New phase 2 trial NCT02465060 posted by National Cancer Institute (NCI): "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)". New trial on a phase 2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 11 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.